Intramuscular clodronate therapy in postmenopausal osteoporosis

Area of Science:

• Endocrinology
• Orthopedics
• Pharmacology

Background:

• Oral bisphosphonates are effective for postmenopausal osteoporosis but may have compliance issues.
• Intramuscular (i.m.) clodronate offers an alternative administration route for osteoporosis treatment.

Purpose of the Study:

• To evaluate the efficacy of intermittent i.m. clodronate in treating postmenopausal osteoporosis.
• To compare weekly versus bi-weekly i.m. clodronate administration for bone mineral density (BMD) changes.

Main Methods:

• A 3-year randomized controlled study involving 90 osteoporotic postmenopausal women.
• Patients received calcium supplementation and were randomized to no therapy, 100 mg i.m. clodronate weekly, or 100 mg i.m. clodronate every two weeks.
• Bone mineral density (BMD) and biochemical markers of bone turnover were monitored.

Main Results:

• Intramuscular clodronate significantly increased spinal BMD compared to controls, with greater gains in the weekly group (4.5% over 3 years).
• Significant increases in trochanter and Ward's triangle BMD were observed with weekly injections at 12 months.
• Hip BMD changes differed significantly from controls in both i.m. clodronate groups; however, femoral neck BMD did not change significantly.
• Biochemical markers of bone turnover were suppressed in both clodronate treatment groups.
• Nearly 50% of patients on weekly i.m. clodronate withdrew due to injection site pain.

Conclusions:

• Intermittent i.m. clodronate administration demonstrates clinically relevant benefits for skeletal bone density in postmenopausal osteoporosis.
• The significant pain associated with i.m. injections may restrict the extensive clinical application of this bisphosphonate therapy.